Krystal Biotech (KRYS) Surges 125% Following Positive Topline Results from GEM-3 Pivotal Trial of VYJUVEK in Patients with Dystrophic Epidermolysis Bullosa

Go back to Krystal Biotech (KRYS) Surges 125% Following Positive Topline Results from GEM-3 Pivotal Trial of VYJUVEK in Patients with Dystrophic Epidermolysis Bullosa
(NASDAQ: KRYS) Delayed: 56.93 +1.96 (3.57%)
Previous Close $54.97    52 Week High
Open $54.90    52 Week Low
Day High $57.29    P/E N/A 
Day Low $54.46    EPS
Volume 122,652